Thymoglobulin® Pharmacokinetics in Patients Undergoing Hematopoietic Stem Cell Transplantation

This study is examining how a medication called Thymoglobulin (anti-thymocyte globulin) behaves in the body — specifically its pharmacokinetics (how the drug is absorbed, distributed, and cleared) — in patients undergoing their first hematopoietic stem cell transplant (HSCT). HSCT is used to treat serious blood cancers and immune disorders, and Thymoglobulin is given beforehand to suppress the immune system and prevent rejection. Knowing exactly how the drug moves through the body could help doctors dose it more precisely and improve transplant outcomes. The study includes patients aged 2 and older who are receiving Thymoglobulin as part of their first HSCT, are enrolled in the French national health system, and have a performance score of 50% or above. Patients who have received similar serotherapy in the past 3 months, have uncontrolled infections, are pregnant, or are in another drug trial are not eligible. This research is important because optimal Thymoglobulin dosing is challenging — too little may allow graft rejection, while too much can lead to severe immune suppression, infections, or Epstein-Barr virus-related complications. By building a precise pharmacokinetic model across ages (including children), this study could lead to personalized dosing protocols that improve the success of stem cell transplantation for patients with leukemia, lymphoma, and other life-threatening conditions.